PFE - Pfizer Inc.
| Previous Close | 43.21 |
| Open | 43.10 |
| Bid | 43.49 x 3000 |
| Ask | 0.00 x 1100 |
| Day's Range | 42.91 - 43.78 |
| 52 Week Range | 33.20 - 45.81 |
| Volume | 23,343,969 |
| Avg. Volume | 21,864,193 |
| Market Cap | 251.508B |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | 10.99 |
| EPS (TTM) | 3.96 |
| Earnings Date | Jan 28, 2019 - Feb 1, 2019 |
| Forward Dividend & Yield | 1.36 (3.07%) |
| Ex-Dividend Date | 2018-11-08 |
| 1y Target Est | 43.79 |
- The Wall Street Journal•14 hours ago
[$$] Pfizer to Raise Prices on 41 Drugs in January
Pfizer Inc. plans to resume its practice of raising drug prices early next year after bowing to pressure from President Trump over the summer when the company rolled back some increases. Pfizer, among the world’s biggest drugmakers by sales, won’t be raising prices as much as it has in past years. It said it would raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January.
- Reuters•16 hours ago
Pfizer to raise US drug prices in January after previously backing down
Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump. Pfizer said it would raise the list price of most of the drugs by 5 percent, while prices for three will rise by 3 percent, and the price of one by 9 percent, all effective Jan. 15. Pfizer said it does not expect the price increases to boost its revenue in the United States next year as it believes that rebates to insurance companies and pharmacy benefit managers (PBMs) will offset them.
- American City Business Journals•17 hours ago
Pfizer to raise drug prices in January
Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10 percent of its portfolio, in January. According to The Wall Street Journal, citing an unnamed source, most of the planned increases will be 5 percent, while three of the drugs’ list prices will go up by 3 percent. One of the drug prices will go up by 9 percent, the report continued.
- MarketWatch•17 hours ago
Pfizer to raise prices on 41 drugs: report
Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January, The Wall Street Journal reported Friday, citing a person familiar with the matter. Most of the increases will be around 5% and would take effect Jan. 15, the person said, according to the WSJ. Pfizer rolled back some increases in July under criticism from President Donald Trump, but earlier this month Chief Executive Ian Read said Pfizer was likely to go back to price hikes in January. Shares of Pfizer rose 0.1% in the extended session Friday after ending the regular trading day up 0.7%.
- TheStreet.com•17 hours ago
Pfizer Plans Price Hikes for 41 Drugs Next Year
said Friday, Nov. 16, it plans to increase list prices for 41 of its drugs effective Jan. 15. The plan was first reported by The Wall Street Journal. "The only exceptions are three products that have a 3% increase and one product that is increasing 9% due to the completion of two extensive development programs that have led to the recent FDA approvals of two new medical uses that meet unmet patient needs," Pfizer said.
- CNBC•18 hours ago
Pfizer to raise prices on 41 prescription drugs next year despite pressure from Trump
Pfizer will raise list prices on 41 prescription drugs in January. Pfizer this summer deferred planned price increases after President Donald Trump criticized the drug giant. Trump said Pfizer and other drugmakers "should be ashamed" of themselves.
Bloomberg•yesterdayAstraZeneca Shows It Can Still Take Some Knocks
On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.
Markit•yesterdaySee what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
- Financial Times•yesterday
[$$] Pfizer to raise prices for 41 drugs despite Trump criticism
Pfizer said it would increase the price of 41 products in its drug portfolio, just four months after having initially put off those plans amid heavy criticism from US President Donald Trump. — after Mr Trump said it should be “ashamed” of the move and that it and other rivals were “taking advantage of poor people”. Effective January 15, 2019, prices for 37 of the products will rise by 5 per cent, while three products will see prices rise by 3 per cent, and one by 9 per cent.
- Zacks•2 days ago
Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.
- Motley Fool•2 days ago
Why Pfizer Is Up 19% in 2018 So Far
Here's what has investors revved up about the big pharma stock.
- Motley Fool•2 days ago
3 Dividend Stocks Ideal for Retirees
If you're looking for a solid income stream to complement Social Security and saving, check out these three great dividend stocks.
- Motley Fool•3 days ago
Here's Why Sangamo Therapeutics Lost 12% Today
Wall Street is growing increasingly concerned about the progress the company's making with a gene therapy for hemophilia A.
- Reuters•3 days ago
Pfizer loses drug patent fight in UK top court, may face claims
Pfizer (PFE.N) lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan (AGN.N), and Mylan (MYL.O). Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.
Reuters•3 days agoPfizer loses drug patent fight in UK top court, may face claims
Pfizer lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan, and Mylan. Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.
- Kiplinger•3 days ago
7 Highest-Yielding Dow Dividend Stocks
Volatile markets like today's are a good time to remind long-term investors of the virtues of big, stable dividend stocks like those found in the Dow Jones Industrial Average. It's hard to beat blue-chip dividend stocks when it comes to long-term performance. Witness the highest-yielding Dow dividend stocks. Although not every name is necessarily a buy at current levels, each and every one has distinguished itself over the decades. Note that many of the highest-yielding Dow dividend payers rank among the best equity investments of all time. In several instances, these stocks remain top picks among Wall Street analysts, mutual fund managers and hedge fund managers today. Big, healthy balance sheets and reliable and rising dividends also tend to make the highest-yielding dividend stocks in the Dow Jones less volatile than the broader market. That can help income investors sleep better at night. Here are the highest-yielding Dow dividend stocks, with yields ranging from just more than 3% to over 5%. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
- Reuters•4 days ago
Walmart, Home Depot adopt health insurer tactic in drug copay battle
Walmart and Home Depot , two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards for everything from multiple sclerosis treatments to widely-used rheumatoid arthritis medications sold through a specialty pharmacy.
- Zacks•5 days ago
Pfizer (PFE) Stock Moves -0.38%: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $44.11, marking a -0.38% move from the previous day.
- Investor's Business Daily•5 days ago
These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
- Market Realist•5 days ago
Corbus Pharmaceuticals Holdings’ Performance in 2018
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
Market Realist•5 days agoHow Nektar Performed in the Third Quarter
Nektar Therapeutics (NKTR) released its third-quarter results on November 8. On November 6, Nektar announced a clinical oncology collaboration with Pfizer (PFE) to evaluate the combination of NKTR-214 with avelumab and talazoparib in different cancer areas. Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the comparable period of 2017.
- Insider Monkey•6 days ago
Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
- Motley Fool•6 days ago
Better Buy: Amgen Inc. vs. Pfizer Inc.
Which big drugmaker is the better pick for long-term investors?
- CNBC Videos•21 hours ago
Final Trades: Virtu, JPMorgan & Pfizer
The "Halftime Report" traders give their top stocks to watch for the second half.
